CN109985156A - A kind of lily with antidepressant effect, anemarrhena asphodefoides extract - Google Patents
A kind of lily with antidepressant effect, anemarrhena asphodefoides extract Download PDFInfo
- Publication number
- CN109985156A CN109985156A CN201910355802.7A CN201910355802A CN109985156A CN 109985156 A CN109985156 A CN 109985156A CN 201910355802 A CN201910355802 A CN 201910355802A CN 109985156 A CN109985156 A CN 109985156A
- Authority
- CN
- China
- Prior art keywords
- extract
- lily
- preparation
- anemarrhena asphodefoides
- antidepressant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The disclosure belongs to natural drug extract technical field, and in particular to a kind of lily anemarrhena asphodefoides extract, preparation method and application.This field thinks that lily anemarrhena total saponin has antidepressant activity for the research of antidepressant activity in lily rhizoma anemarrhenae, can be by increasing the hyperfunction function of intracerebral neurotransmitter, reverse hypothalamus-pituitary-adrenal axis (HPA) s function.The previous research of inventor has shown that the furostanol saponin in lily, anemarrhena asphodefoides extract has good antidepressant activity.Present disclose provides a kind of lily anemarrhena asphodefoides extracts, there is good extraction effect for furostanol saponin, verified through animal model, which can be effectively improved depressed Animal Behavior Science and show, increase mediator secretion in animal brain, is expected to become the antidepressant having good prospects.
Description
Technical field
The disclosure belongs to natural drug extract technical field, and in particular to a kind of preparation method of lily anemarrhena asphodefoides extract
And its application in preparation antidepressant.
Background technique
The information for disclosing the background technology part is merely intended to increase the understanding to the general background of the disclosure, without certainty
It is considered as recognizing or implying in any form that information composition has become existing skill well known to persons skilled in the art
Art.
Lilii and Anemarrhenae Decoction comes from " Synopsis Golden Chamber " volume.Lily, moistening lung and clearing away the heart-fire, benefiting qi for tranquillization；Rhizoma anemarrhenae, clearing heat and promoting fluid are removed
It is tired to moisturize.The solvent spring of the party is special, and Gu Bencao thinks that it has beneficial the five internal organs, clearing lung-heat stomach, lower hot gas, diuresis effect.Three
Person plays qi-restoratives, heat-clearing, yin-nourishing.Lily is sweet to tremble with fear clear and rich and oiliness, and the sweet cold fall fire of rhizoma anemarrhenae is without dry, and lily is relatively mended, rhizoma anemarrhenae
It relatively rushes down, two medicine compatibilities, a profit one is clear, and one, which mends one, rushes down, and plays moistening lung and clearing heat, the function of antitoxic heart-soothing and sedative altogether.Tcm clinical practice is usually used in controlling
Treat depression, insomnia, asthma, the diseases such as quench one's thirst.
Modern medicine study thinks that the clinical manifestation of disorder of emotion and the diagnostic criteria of depression are more similar, for lily
Antidepressant active constituent and mechanism of action expand correlative study in Anemarrhenae Decoction.Existing research thinks that saponin component is lily
Antidepressant activity ingredient in Anemarrhenae Decoction, can be by increasing intracerebral neurotransmitter, reversing hypothalamus-pituitary-adrenal axis
(HPA) the hyperfunction function of s function.Inventor's early-stage study shows Lilium brownie, the content of timosaponin vitro extraction and dynamic
Exposed amount differs greatly in vivo after object is oral, and the distributed degrees difference of different saponin constituents each internal organs in vivo is also larger,
Middle furostanol saponin has higher exposed amount in brain by oral administration, and has good antidepressant activity.It has been recognised by the inventors that existing
Extracting method in technology for saponin(e is mostly solvent extraction method, and for the extraction of furostanol saponin research more blank.
Sphingol single-cell is a kind of novel microbial resource abundant, can be used for the biodegrade of aromatic compound, is had
Having the aromatic compound difficult to degrade of higher metabolic capability, especially labyrinth has the effect of specificity.Jin Yan's et al.
A kind of Sphingol single-cell 2-F2 is provided in research has the effect for converting the main saponin(e Re of ginseng to the rare saponin(e Rh1 of ginseng
Fruit.
Summary of the invention
For the studies above background, inventor thinks to provide a kind of high efficiency extraction lily, furostanol saponin constituents in rhizoma anemarrhenae
Method have great importance for the treatment of the mental disorders such as depression.Present disclose provides a kind of extractions of lily rhizoma anemarrhenae
Object contains more furostanol saponin in the extract, can be relatively good penetrate blood-brain barrier.It is verified by animal model, it should
Extract can significantly improve the behaviouristics performance of depressed animal, increase the mediator content of intracerebral, be applied to antidepressant
Exploitation be of great significance.In addition, the disclosure also provides the preparation method of above-mentioned lily anemarrhena asphodefoides extract, pass through organic solvent
Extraction combines the degradation of microorganism, and the complicated saponin(e in organic extract is degraded to furan steroid soap through certain fermenting procedure
Glycosides significantly improves the content of the furostanol saponin in extract.
For the disclosure in a first aspect, providing a kind of preparation method of lily anemarrhena asphodefoides extract, the preparation method includes following
Step: being added alcoholic solution through diacolation and obtain alcohol extract in Xiang Baihe, rhizoma anemarrhenae, the organic phase removed in alcohol extract is concentrated under reduced pressure and obtains
Medicinal extract；Medicinal extract is soluble in water, it sequentially adds organic phase and is extracted, retain organic phase part, remove solvent and obtain coarse extraction,
The inverted ginsenoside Sphingol single-cell of the crude extract (Sphingomonas ginsenosidimutans) is fermented, is obtained
Obtain the lily anemarrhena asphodefoides extract.
Preferably, above-mentioned preparation method further includes the steps that using column chromatographic purifying.
Disclosure second aspect provides the lily anemarrhena asphodefoides extract that preparation method described in first aspect obtains.
The disclosure third aspect provides the answering in preparation antidepressant of lily anemarrhena asphodefoides extract described in second aspect
With.
Compared with prior art, the beneficial effect of the disclosure is:
Present disclose provides a kind of preparation method with lily anemarrhena asphodefoides extract, the lily rhizoma anemarrhenae prepared by this method
The furostanol saponin and derivative for containing more content in extract, can preferably penetrate blood-brain barrier, have good behavior
The technical effect that learning improves and improve intracerebral mediator content has great importance applied to the preparation of antidepressant.
Detailed description of the invention
The Figure of description for constituting a part of this disclosure is used to provide further understanding of the disclosure, and the disclosure is shown
Meaning property embodiment and its explanation do not constitute the improper restriction to the disclosure for explaining the disclosure.
Fig. 1 is animal pattern changes of weight line chart in embodiment 2；
Fig. 2 is behaviouristics result column diagram in embodiment 2；
Wherein Fig. 2A is forced swimming result column diagram；Fig. 2 B is Elevated plus-maze result column diagram；Fig. 2 C is spacious field
Experimental result column diagram；Fig. 2 D is tail-suspention test result column diagram.
Fig. 3 is that 2 Biochemical Indexes of embodiment investigate result.
Fig. 3 A is DOPAMINE CONTENT IN RABBIT column diagram in animal pattern brain；Fig. 3 B is 5-HT content cylindricality in animal pattern brain
Figure.
Specific embodiment
It is noted that following detailed description is all illustrative, it is intended to provide further instruction to the disclosure.Unless another
It indicates, all technical and scientific terms used herein has usual with disclosure person of an ordinary skill in the technical field
The identical meanings of understanding.
It should be noted that term used herein above is merely to describe specific embodiment, and be not intended to restricted root
According to the illustrative embodiments of the disclosure.As used herein, unless the context clearly indicates otherwise, otherwise singular
Also it is intended to include plural form, additionally, it should be understood that, when in the present specification using term "comprising" and/or " packet
Include " when, indicate existing characteristics, step, operation, device, component and/or their combination.
As background technique is introduced, lily rhizoma anemarrhenae is thought for the research of antidepressant activity in lily rhizoma anemarrhenae in this field
Total saposins have antidepressant activity, can be by increasing intracerebral neurotransmitter, reversing hypothalamus-pituitary-adrenal axis (HPA) axis
Function hyperactivity.The previous research of inventor has shown that the furostanol saponin in lily, anemarrhena asphodefoides extract has good antidepression
Activity.Present disclose provides a kind of lily anemarrhena asphodefoides extracts, have good extraction effect for furostanol saponin, through animal model
Verifying, the extract can be effectively improved depressed Animal Behavior Science and show to increase mediator secretion in animal brain, be expected to become prospect
Good antidepressant.
For the disclosure in a first aspect, providing a kind of preparation method of lily anemarrhena asphodefoides extract, the preparation method includes following
Step: being added alcoholic solution through diacolation and obtain alcohol extract in Xiang Baihe, rhizoma anemarrhenae, the organic phase removed in alcohol extract is concentrated under reduced pressure and obtains
Medicinal extract；Medicinal extract is soluble in water, it sequentially adds organic phase and is extracted, retain organic phase part, remove solvent and obtain coarse extraction,
The inverted ginsenoside Sphingol single-cell of the crude extract (Sphingomonas ginsenosidimutans) is fermented, is obtained
Obtain the lily anemarrhena asphodefoides extract.
Preferably, above-mentioned preparation method further includes the steps that using column chromatographic purifying.
In some embodiments, the lily, rhizoma anemarrhenae mass ratio be 4~6:1~3.
In some embodiments, the ethyl alcohol that the alcoholic solution is 60~80%.
In some embodiments, the alcoholic solution is 8~12 times of volumes of lily rhizoma anemarrhenae.
In some embodiments, the diacolation speed is 2~4mL/min.
In some embodiments, it after the medicinal extract is soluble in water, sequentially adds ethyl acetate and chloroform is extracted.
In some embodiments, the column chromatography steps are as follows: methanol dissolution, loading column is added in lily anemarrhena asphodefoides extract
Chromatography is eluted, and is collected whole eluents removing solvents and is obtained the lily anemarrhena asphodefoides extract.Further, the leacheate is
Methanol-water, volume ratio are 55~65:35~45.
In some embodiments, the inverted ginsenoside Sphingol single-cell (Sphingomonas of the crude extract
Ginsenosidimutans the step of) fermenting is as follows: fluid nutrient medium wiring solution-forming, inoculation conversion people being added into crude extract
Join saponin(e Sphingol single-cell (Sphingomonas ginsenosidimutans) seed liquor, it is fermented pass the lily is known
Female extract.
Disclosure second aspect provides the lily anemarrhena asphodefoides extract that preparation method described in first aspect obtains.
The disclosure third aspect provides the answering in preparation antidepressant of lily anemarrhena asphodefoides extract described in second aspect
With.
In some embodiments, the antidepressant is 5-HT agonist.
In some embodiments, the antidepressant is DA agonist.
In order to enable those skilled in the art can clearly understand the technical solution of the disclosure, below with reference to tool
The technical solution of the disclosure is described in detail in the embodiment and comparative example of body.
Reagent and medicinal material in following embodiment are commercial product, and those skilled in the art can voluntarily buy.Conversion
Ginsenoside Sphingol single-cell (Sphingomonas ginsenosidimutans) CICC 10895 is micro- purchased from Chinese industrial
Biological inoculum preservation administrative center.
The preparation of 1 extract of embodiment
It is coated in filter paper after weighing 50g lily, the mixing of 20g rhizoma ane marrhenae coarse powder, is placed in percolator, 10 times of bodies are added
70% long-pending ethyl alcohol carries out seepage pressure effects, and diacolation speed is 3mL/ minutes, obtains alcohol extract.Alcohol extracting is removed by being concentrated under reduced pressure
Ethyl alcohol in liquid obtains medicinal extract.
It weighs 3mg medicinal extract and the dissolution of 20mL water is added, 15mL ethyl acetate is added by several times into solution and is extracted, every time
5mL, combining extraction liquid obtain ethyl acetate portion.Continue the addition 15mL chloroform into remaining aqueous phase solution to be extracted, often
Secondary 5mL, combining extraction liquid obtain chloroform portion.Having in ethyl acetate portion and chloroform portion is removed respectively by being evaporated under reduced pressure
Solvent obtains lily rhizoma anemarrhenae crude extract.
Weighing 0.5mg crude extract addition 6mL methanol dissolves its all, and a small amount of column chromatography silica gel is added and mixes sample, passes through
Silica gel column chromatography carries out elution separation, and leacheate is methanol-water (60:40), collects whole eluents again by vacuum distillation
To no alcohol taste, organic phase is removed, extract 1 is obtained by vacuum drying.
The preparation of 2 extract of embodiment
Ginsenoside Sphingol single-cell (Sphingomonas ginsenosidimutans) CICC 10895 will be converted
It is inoculated in R2A culture medium, cultivates under 37 DEG C of aerobic conditions and activated for 24 hours, repeat the operation and obtain re-activation bacterial strain, choose
The good bacterium colony of vigor is selected to expand culture the seed liquor for obtaining strain.
The lily rhizoma anemarrhenae crude extract prepared in embodiment 1 addition R2A culture medium is made into 1.2mg/ml solution.After activating
Strain seed liquor be added in configured solution with 3% inoculum concentration, cultivate 7d under 28 DEG C of aerobic conditions, obtain fermentation and produce
Object.
By tunning through 0.5 μm of membrane filtration, 0.5mg tunning addition 6mL methanol is weighed after dry makes its whole
Dissolution, is added a small amount of column chromatography silica gel and mixes sample, carries out elution separation by silica gel column chromatography, leacheate be methanol-water (60:
40) whole eluents, are collected again by vacuum distillation to no alcohol taste, remove organic phase, extract is obtained by vacuum drying
2。
The antidepressant activity of 3 rhizoma anemarrhenae Bulbus Lilii extract of embodiment is studied
1. material
1.1 animal
SPF grades of adult male SD rats, 150~180g of weight please experimental animal purchased from Jinan friend and breed Co., Ltd, move
Object license number SCXK (Shandong) 20140008.
2. method
The preparation of 2.1 animal models
Induced rat depression model is mildly stimulated using chronic Unpredictability in the present embodiment.All rat adaptability are raised
It supports and is grouped after a week, including blank group, model group, administration group and positive drug group.6/cage of blank group rat, model
Group, administration group and positive drug group every 8, every cage one is only raised, and all rats freely can ingest and drink water, and every three
Its replacement padding.
Wherein, blank group is not dealt with, and model group and gives chronic stimulation, stimulation mode packet weekly in administration group continuous six weeks
It includes: prohibiting water (for 24 hours), fasting (for 24 hours), hot water swimming (45 DEG C, 5min), ice water swimming (4 DEG C, 5min), high speed concussion
Barrier (for 24 hours), folder tail (20min), constraint (2h) in (10min), moist padding (for 24 hours), cage, a kind of daily random arrangement, together
Kind stimulation is discontinuous to be occurred.
It is administered while administration group and positive drug group rat modeling, administration group gives the lily rhizoma anemarrhenae of the preparation of embodiment 2
Extract, it is 100mg/kg that premenstruum (premenstrua) MTT experiment, which establishes dosage,.Positive drug group gives Prozac, and dosage is
Drug is suspended in 0.5% sodium carboxymethylcellulose through gastric infusion by 8mg/kg, and blank group and model group are same daily
Moment gives the sodium carboxymethylcellulose blank solution of equal volume.
The observation of 2.2 changes of body mass
It weighs to rat upgrading amount weekly, calculates every group of animal average weight, as a result as shown in table 1 below, and draw
When m- weight line chart, as a result as shown in Figure 1.
1 animal pattern changes of weight situation table of table
Note: compared with model group, " * " indicates that p < 0.05 " * * " indicates p < 0.01.
It can be seen that model group, administration group and positive drug group since second week in conjunction with table 1 and Fig. 1, weight is compared to sky
White group there is more significant reduction.Since third week, administration group and positive drug group and model group start to occur more
Significant difference, it was demonstrated that extract and positive drug that the disclosure provides can improve the feelings of rat model continued weight decline
Shape.And until the 6th week, rat and the positive drug group rat body weight difference for taking lily anemarrhena asphodefoides extract are unobvious, it was demonstrated that
The extract can preferably keep spiritual expression of the rat model during test, maintain the growth of weight.
2.3 behaviouristics result is investigated
Each experimental mice is pressed down by forced swim test, Elevated plus-maze, spacious field experiment and tail-suspention test respectively
Yu Chengdu is evaluated, as a result as shown in Fig. 2, model group rats are after the unpredictable mild stimulation of experience, in Behavioral assessment
The whole residence time is elongated in test, and movement active list now drops, it was demonstrated that depressed table has been prepared in the present embodiment modeling success
Existing rat model.
It can be seen that administration group and positive drug by forced swimming, Elevated plus-maze, spacious field experiment and tail-suspention test
Overall performance of the rat of group in behaviouristics evaluation experimental will be enlivened more compared to model group, and difference has statistical significance
(p<0.01).In addition, performance difference of the rat of administration group and positive drug group in four groups of Behavioral assessments is unobvious, do not have
It is statistically significant, it was demonstrated that the extract that the disclosure provides can effectively alleviate the behaviouristics performance for improving depression rat, and
And improvement is close to the effect of positive drug.
2.4 biochemical indicators are investigated
After experiment in six weeks, each experimental group rat is put to death, detects dopamine D A and serotonin 5-HT in brain area
Changes of contents, as a result as shown in Figure 3.
Such as Fig. 3, model group rats intracerebral dopamine and 5-HT are reduced compared to blank group with more significant, take this public affairs
The content for opening extract and positive drug intracerebral neurotransmitter is obviously improved, it was demonstrated that the rhizoma anemarrhenae lily of disclosure preparation is extracted
Object more can significantly improve the secretion situation of intracerebral neurotransmitter, and depressive symptom is effectively relieved.
The detection of content of furostanol saponin in 2.5 extracts
It is accurate respectively to weigh dry furostanol saponinⅠ, timosaponin N, timosaponin L10mg in 50mL round-bottomed flask,
Methanol 20mL reflux is added to let cool, obtains reference substance solution.It weighs three parts of extracts 1 at random and extract 2 is made in the same way
Available test sample solution.
Liquid phase chromatogram condition: chromatographic column SHIMADZU Shim pack VP ODS (4.6mm × 250mm), mobile phase second
Nitrile-water (25:75), flow velocity 1.0mL/min-1, 20 μ L of sample volume.Content through each furostanol saponin in Detection and Extraction object such as following table institute
Show:
The content (%) of furostanol saponin in 2 extract of table
The content of common above-mentioned three kinds of furostanol saponins is detected in selection rhizoma anemarrhenae, lily, and testing result table as above is real
It applies in the extract that in example 1 prepared by method, the content adduction of three kinds of furostanol saponins is 6.63%, and the hair of bacterium is passed through in embodiment 2
The content summation of above-mentioned three kinds of furostanol saponins is more than the 50% of extract in the lily anemarrhena asphodefoides extract of ferment effect preparation, it was demonstrated that should
It is rich in the ingredient of furostanol saponin class in extract, converts ginsenoside Sphingol single-cell (Sphingomonas
Ginsenosidimutans) it effectively can be converted into furostanol saponin using the other compositions in lily rhizoma anemarrhenae as substrate, significantly
Improve the content of furostanol saponin in extract.
The foregoing is merely preferred embodiment of the present disclosure, are not limited to the disclosure, for the skill of this field
For art personnel, the disclosure can have various modifications and variations.It is all within the spirit and principle of the disclosure, it is made any to repair
Change, equivalent replacement, improvement etc., should be included within the protection scope of the disclosure.
Claims (10)
1. a kind of preparation method of lily anemarrhena asphodefoides extract, which is characterized in that the preparation method comprises the following steps: to hundred
Alcoholic solution is added in conjunction, rhizoma anemarrhenae and obtains alcohol extract through diacolation, the organic phase removed in alcohol extract is concentrated under reduced pressure and obtains medicinal extract；It will leaching
Cream is soluble in water, sequentially adds organic phase and is extracted, and retains organic phase part, removes solvent and obtains coarse extraction, will be described thick
The inverted ginsenoside Sphingol single-cell of extract (Sphingomonas ginsenosidimutans) fermentation, obtains described hundred
Close anemarrhena asphodefoides extract；Preferably, the preparation method further includes the steps that using column chromatographic purifying.
2. preparation method as described in claim 1, which is characterized in that the lily, rhizoma anemarrhenae mass ratio be 4~6:1~3.
3. preparation method as described in claim 1, which is characterized in that the ethyl alcohol that the alcoholic solution is 60~80%；Or it is described
Alcoholic solution is 8~12 times of volumes of lily rhizoma anemarrhenae.
4. preparation method as described in claim 1, which is characterized in that the diacolation speed is 2~4mL/min.
5. preparation method as described in claim 1, which is characterized in that after the medicinal extract is soluble in water, sequentially add acetic acid second
Ester and chloroform are extracted.
6. preparation method as described in claim 1, which is characterized in that the inverted ginsenoside Sphingomonas of crude extract
The step of bacterium (Sphingomonas ginsenosidimutans) is fermented is as follows: fluid nutrient medium being added into crude extract and is made into
Solution, inoculation conversion ginsenoside Sphingol single-cell (Sphingomonas ginsenosidimutans) seed liquor, through sending out
Ferment passes to obtain the lily anemarrhena asphodefoides extract.
7. the lily anemarrhena asphodefoides extract that any one of claim 1-6 preparation method obtains.
8. application of the lily anemarrhena asphodefoides extract as claimed in claim 7 in preparation antidepressant.
9. application as claimed in claim 8, which is characterized in that the antidepressant is 5-HT agonist.
10. application as claimed in claim 8, which is characterized in that the antidepressant is DA agonist.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910355802.7A CN109985156A (en) | 2019-04-29 | 2019-04-29 | A kind of lily with antidepressant effect, anemarrhena asphodefoides extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910355802.7A CN109985156A (en) | 2019-04-29 | 2019-04-29 | A kind of lily with antidepressant effect, anemarrhena asphodefoides extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109985156A true CN109985156A (en) | 2019-07-09 |
Family
ID=67135709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910355802.7A Pending CN109985156A (en) | 2019-04-29 | 2019-04-29 | A kind of lily with antidepressant effect, anemarrhena asphodefoides extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109985156A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872319A (en) * | 2012-09-15 | 2013-01-16 | 包头中药有限责任公司 | Traditional Chinese medicine extract of total saponin ingredients and preparation method of same |
| CN103183715A (en) * | 2011-12-30 | 2013-07-03 | 中国科学院上海药物研究所 | Furostan saponin derivative and purpose thereof |
-
2019
- 2019-04-29 CN CN201910355802.7A patent/CN109985156A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103183715A (en) * | 2011-12-30 | 2013-07-03 | 中国科学院上海药物研究所 | Furostan saponin derivative and purpose thereof |
| CN102872319A (en) * | 2012-09-15 | 2013-01-16 | 包头中药有限责任公司 | Traditional Chinese medicine extract of total saponin ingredients and preparation method of same |
Non-Patent Citations (4)
| Title |
|---|
| 姜霞: "百合皂苷成分研究 ", 《农业科技与信息》 * |
| 帅颖: "百合、百合知母汤有效部位的富集及含量测定的研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 罗永明主编: "《天然药物化学》", 31 August 2011, 华中科技大学出版社 * |
| 金艳等: "鞘氨醇单胞菌2 -F2将人参主皂苷Re转化为人参稀有皂苷Rh1", 《延边大学农学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102367424B (en) | Coriobacterium sp. AUH-Julong21 and use of coriobacterium sp. AUH-Julong21 in liquiritigenin conversion | |
| Zhang et al. | Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20 (S)-protopanaxadiol in mice models of despair | |
| Wang et al. | Antidepressant-like effects of the active acidic polysaccharide portion of ginseng in mice | |
| CN110934803B (en) | Plant fermentation composition with whitening and spot-fading functions | |
| Murthy et al. | Efficacy of ginseng adventitious root extract on hyperglycemia in streptozotocin-induced diabetic rats | |
| CN101095710A (en) | Method for improving the main efficacy composition of panax notoginseng through zymolysis | |
| CN112618614B (en) | Rosa roxburghii active extract with anti-depression effect and application thereof | |
| CN105748622A (en) | Probiotic fermented traditional Chinese medicine composition for spasmolysis and analgesia and preparation method and application thereof | |
| Singh et al. | Ethnopharmacological applications targeting alcohol abuse: overview and outlook | |
| CN101138576A (en) | Codonopsis pilosula fermentation liquor and uses thereof | |
| CN109504615A (en) | Simple form Megamonas (Megamonas funiformis) and its application | |
| Luo et al. | Tianhuang formula reduces the oxidative stress response of NAFLD by regulating the gut microbiome in mice | |
| CN109771503A (en) | A kind of pepper extract and its application | |
| CN102676627A (en) | Microbial fermentation extraction method of total arasaponin | |
| Nikolaou et al. | Accidental poisoning after ingestion of “aphrodisiac” berries: diagnosis by analytical toxicology | |
| CN116492385B (en) | Compound essential oil for repairing skin and pharmaceutical composition containing compound essential oil | |
| CN105998222B (en) | The composition and its preparation method and application of probiotics fermention unprocessed Radix Aconiti Lateralis | |
| CN109985156A (en) | A kind of lily with antidepressant effect, anemarrhena asphodefoides extract | |
| CN109468359B (en) | Ginsenoside Rk6Preparation method of (1) | |
| CN106666703A (en) | Enzyme composition with liver-protecting function, as well as preparation and preparation method thereof | |
| CN106581592A (en) | Use of turmeric extract in preparation of products used for preventing drunkenness and alleviating drunkenness and having auxiliary effect on chemical liver injury | |
| CN115569156B (en) | Ginseng and ganoderma lucidum fungus extract for remarkably improving bronchial asthma inflammation and application thereof | |
| KR20120053564A (en) | Fermented ginseng with ganoderma lucidum beverage manufacturing method and that beverage | |
| CN110062806A (en) | Excrement anaerobism bar bacterium (Anaerostipes caccae) and its application | |
| CN111759952A (en) | Application of dendrobe extract in preparation of drugs for regulating cholesterol metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190709 |